Two Cases with Adenoid Cystic Carcinoma with Epidermal Growth Factor Receptor and c-KIT
Yıl: 2022 Cilt: 36 Sayı: 2 Sayfa Aralığı: 118 - 120 Metin Dili: İngilizce DOI: 10.14744/IGH.2022.53824 İndeks Tarihi: 16-09-2022
Two Cases with Adenoid Cystic Carcinoma with Epidermal Growth Factor Receptor and c-KIT
Öz: Adenoid cystic carcinoma of the lung (ACCL) is a very rare tumor with a slow course. Primary treatment is surgery. However, recurrences are common. Although chemo therapy is an option in cases not suitable for surgery, response rates are quite low. Identifying the tumor-specific biology and individualized treatment play an important role in these patients. We detected epidermal growth factor receptor (EGFR) positivity and c-KIT positivity by molecular profiling performed in two of our patients diagnosed with ACCL. We evaluated the efficacy of erlotinib and imatinib treatments aimed at these targets. In our case with EGFR positivity due to ACCL and using erlotinib, a 16-month progression-free survival (PES) was found. In our erlotinib used/given case with EGFR positivity due to ACCL, a 16-month PFS was found. In our patient who used imatinib for c-KIT, PFS was observed to be 9 months. Longer survivals were achieved with both treatments compared to chemotherapies. Low survival rates have been found with chemotherapies in locally advanced and metastatic ACCL patients. Molecular profiling plays a very important role in this disease group for patients.
Anahtar Kelime: Epidermal Büyüme Faktör Reseptörü ve c-KIT Pozitif Adenoid Kistik Karsinomlu İki Olgu
Öz: Akciğerin adenoid kistik karsinomu yavaş seyirli, çok nadir görülen bir tümördür. Primer tedavisi cerrahidir. Ancak özellikle rekürrensler sık görülmektedir. Cerrahiye uygun olmayan durumlarda kemoterapi bir seçenek olsa da yanıt oranları oldukça düşüktür. Tümöre özgü biyolojiyi belirlemek ve bireyselleştirilmiş tedavi bu hasta larda önemli bir rol oynamaktadır. Akciğerin adenoid kistik karsinomu tanısı alan iki hastada yapılan moleküler profilleme ile EGFR pozitifliği ve c-KIT pozitifliği saptan dı. Bu hedeflere yönelik erlotinib ve imatinib tedavilerinin etkinliği değerlendirildi. Akciğerin adenoid kistik karsinomu nedeniyle EGFR pozitifliği saptanan ve erlotinib kullanan olguda 16 aylık progresyonsuz sağkalım saptandı. c-KIT nedeniyle imati nib kullanan hastada ise progresyonsuz sağkalım dokuz ay olarak gözlendi. Her iki tedavi ile kemoterapilerle elde edilen sağkalımdan daha uzun sağkalımlar elde edildi. Lokal ileri ve metastatik akciğerin adenoid kistik karsinomu hastalarında kemoterapilerle düşük sağkalımlar saptandı. Bu hastalık grubunda moleküler profilleme hastalar açısından çok önemli bir rol oynamaktadır.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Olgu Sunumu Erişim Türü: Erişime Açık
- 1. Lawrence JB, Mazur MT. Adenoid cystic carcinoma: A comparative patho logic study of tumors in salivary gland, breast, lung, and cervix. Hum Pathol 1982;13:916–24.
- 2. Kawashima O, Hirai T, Kamiyoshihara M, Ishikawa S, Morishita Y. Primary adenoid cystic carcinoma in the lung: Report of two cases and therapeutic considerations. Lung Cancer 1998;19:211–7.
- 3. Zhu F, Liu Z, Hou Y, He D, Ge X, Bai C, et al. Primary salivary gland-type lung cancer: Clinicopathological analysis of 88 cases from China. J Tho rac Oncol 2013;8:1578–84.
- 4. Dillon PM, Chakraborty S, Moskaluk CA, Joshi PJ, Thomas CY. Adenoid cystic carcinoma: A review of recent advances, molecular targets, and clinical trials. Head Neck 2016;38:620–7.
- 5. Macarenco RS, Uphoff TS, Gilmer HF, Jenkins RB, Thibodeau SN, Lewis JE, et al. Salivary gland-type lung carcinomas: An EGFR immunohisto chemical, molecular genetic, and mutational analysis study. Mod Pathol 2008;21:1168–75.
- 6. Terhaard CH, Lubsen H, Van der Tweel I, Hilgers FJ, Eijkenboom WM, Marres HA, et al. Salivary gland carcinoma: Independent prognostic fac tors for locoregional control, distant metastases, and overall survival: Re sults of the Dutch head and neck oncology cooperative group. Head Neck 2004;26:681–93.
- 7. Grillo HC, Mathisen DJ. Primary tracheal tumors: Treatment and results. Ann Thorac Surg 1990;49:69–77.
- 8. Kurul IC, Demiroz SM, Celik A, Tuluce K, Aytekin I, Sayan M, et al. Pri mary pulmonary adenoid cystic carcinoma: Report of two cases. Asian Cardiovasc Thorac Ann 2012;20:604–6.
- 9. Huo Z, Wu H, Li S, Liang Z. Molecular genetic studies on EGFR, KRAS, BRAF, ALK, PIK3CA, PDGFRA, and DDR2 in primary pulmonary adenoid cystic carcinoma. Diagn Pathol 2015;10:161.
- 10. Hotte SJ, Winquist EW, Lamont E, MacKenzie M, Vokes E, Chen EX, et al. Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: A Princess Margaret hospital phase II consortium study. J Clin Oncol 2005;23:585–90.
- 11. Demiray M, Sahinbas H, Atahan S, Demiray H, Selcuk D, Yildirim I, et al. Successful treatment of c-kit-positive metastatic Adenoid Cystic Carci noma (ACC) with a combination of curcumin plus imatinib: A case report. Complement Ther Med 2016;27:108–13.
- 12. Dahse R, Driemel O, Schwarz S, Dahse J, Kromeyer-Hauschild K, Berndt A, et al. Epidermal growth factor receptor kinase domain mutations are rare in salivary gland carcinomas. Br J Cancer 2009;100:623–5.
- 13. Macarenco RS, Uphoff TS, Gilmer HF, Jenkins RB, Thibodeau SN, Lewis JE, et al. Salivary gland-type lung carcinomas: An EGFR immunohisto chemical, molecular genetic, and mutational analysis study. Mod Pathol 2008;21:1168–75.
- 14. Fujita M, Matsumoto T, Hirano R, Uchino J, Hirota T, Yamaguchi E, et al. Adenoid cystic carcinoma of the lung with an EGFR mutation. Intern Med 2016;55:1621–4.
- 15. Mendes MA, Barroso A, Campainha S. EGFR-variant adenoid cystic car cinoma of the lung. J Thorac Oncol 2018;13:e178–e181
| APA | Gürsoy P (2022). Two Cases with Adenoid Cystic Carcinoma with Epidermal Growth Factor Receptor and c-KIT. , 118 - 120. 10.14744/IGH.2022.53824 |
| Chicago | Gürsoy Pınar Two Cases with Adenoid Cystic Carcinoma with Epidermal Growth Factor Receptor and c-KIT. (2022): 118 - 120. 10.14744/IGH.2022.53824 |
| MLA | Gürsoy Pınar Two Cases with Adenoid Cystic Carcinoma with Epidermal Growth Factor Receptor and c-KIT. , 2022, ss.118 - 120. 10.14744/IGH.2022.53824 |
| AMA | Gürsoy P Two Cases with Adenoid Cystic Carcinoma with Epidermal Growth Factor Receptor and c-KIT. . 2022; 118 - 120. 10.14744/IGH.2022.53824 |
| Vancouver | Gürsoy P Two Cases with Adenoid Cystic Carcinoma with Epidermal Growth Factor Receptor and c-KIT. . 2022; 118 - 120. 10.14744/IGH.2022.53824 |
| IEEE | Gürsoy P "Two Cases with Adenoid Cystic Carcinoma with Epidermal Growth Factor Receptor and c-KIT." , ss.118 - 120, 2022. 10.14744/IGH.2022.53824 |
| ISNAD | Gürsoy, Pınar. "Two Cases with Adenoid Cystic Carcinoma with Epidermal Growth Factor Receptor and c-KIT". (2022), 118-120. https://doi.org/10.14744/IGH.2022.53824 |
| APA | Gürsoy P (2022). Two Cases with Adenoid Cystic Carcinoma with Epidermal Growth Factor Receptor and c-KIT. İzmir Göğüs Hastanesi Dergisi, 36(2), 118 - 120. 10.14744/IGH.2022.53824 |
| Chicago | Gürsoy Pınar Two Cases with Adenoid Cystic Carcinoma with Epidermal Growth Factor Receptor and c-KIT. İzmir Göğüs Hastanesi Dergisi 36, no.2 (2022): 118 - 120. 10.14744/IGH.2022.53824 |
| MLA | Gürsoy Pınar Two Cases with Adenoid Cystic Carcinoma with Epidermal Growth Factor Receptor and c-KIT. İzmir Göğüs Hastanesi Dergisi, vol.36, no.2, 2022, ss.118 - 120. 10.14744/IGH.2022.53824 |
| AMA | Gürsoy P Two Cases with Adenoid Cystic Carcinoma with Epidermal Growth Factor Receptor and c-KIT. İzmir Göğüs Hastanesi Dergisi. 2022; 36(2): 118 - 120. 10.14744/IGH.2022.53824 |
| Vancouver | Gürsoy P Two Cases with Adenoid Cystic Carcinoma with Epidermal Growth Factor Receptor and c-KIT. İzmir Göğüs Hastanesi Dergisi. 2022; 36(2): 118 - 120. 10.14744/IGH.2022.53824 |
| IEEE | Gürsoy P "Two Cases with Adenoid Cystic Carcinoma with Epidermal Growth Factor Receptor and c-KIT." İzmir Göğüs Hastanesi Dergisi, 36, ss.118 - 120, 2022. 10.14744/IGH.2022.53824 |
| ISNAD | Gürsoy, Pınar. "Two Cases with Adenoid Cystic Carcinoma with Epidermal Growth Factor Receptor and c-KIT". İzmir Göğüs Hastanesi Dergisi 36/2 (2022), 118-120. https://doi.org/10.14744/IGH.2022.53824 |
